Opendata, web and dolomites

MSCFate

Fate of mammary stem cells during tumorigenesis and clinical implications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MSCFate project word cloud

Explore the words cloud of the MSCFate project. It provides you a very rough idea of what is the project "MSCFate" about.

panel    perturbation    regulates    trigger    molecular    cancer    acquires    origin    eventual    chemotherapy    coding    occurs    procr    consequently    cell    hyperactive    mutations    therapy    drug    suggests    differentiation    progression    contribution    ultimately    proliferation    mammary    hypothesize    found    expression    elucidate    pinpoint    cells    pi3k    kinase    pik3ca    models    therapies    heterogeneity    tumor    unbiased    preclinical    explored    event    oncogenic    conditional    breast    responsible    investigation    phenotype    biomarkers    fate    h1047r    vivo    shown    perturb    standard    lineage    clinical    gene    transformation    mechanisms    e545k    events    ing    stem    biology    phosphoinositide    accumulating    catalytic    one    generate    msc    mouse    first    initiate    tissue    inhibitors    homeostasis    portrait    tumors    reports    model    tracing    hypothesis    resistance    promotion    situ    reduces    questions    hotspot    genetic    subunit    poorly    patients    combination    knew    metastasis   

Project "MSCFate" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://bentireslab.org/
 Total cost 175˙419 €
 EC max contribution 175˙419 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 175˙419.00

Map

 Project objective

One of the most challenging questions in breast cancer biology is to elucidate the origin of tumor heterogeneity and its contribution to therapy failure. Accumulating evidence suggests that the cell-of-origin, the cell that acquires the first oncogenic event, may define the molecular portrait of the resulting tumor. The fate of mammary Stem Cells (MSC) upon oncogenic perturbation has been poorly explored. Moreover, the Phosphoinositide 3-kinase (PI3K) pathway regulates proliferation/differentiation of MSC and is found hyperactive in breast cancer cells, for example through mutations in PIK3CA, the gene coding for its catalytic subunit. I hypothesize that expression of PIK3CA mutations will perturb mammary tissue homeostasis, initiate mammary cancer and trigger formation of stem-like cancer cells. Using state-of-the-art in situ genetic lineage tracing, I will determine the fate of MSC (identified recently as Procr cells) after conditional expression of PIK3CA hotspot mutations (H1047R, E545K). I will also characterize early molecular events responsible for promotion of transformation (Aim 1). When tumors develop, I will determine tumor phenotype and eventual progression to metastasis (Aim 2). Consequently, this study will generate a new mouse model of breast cancer that will be useful for preclinical studies. A panel of PI3K inhibitors is currently under Clinical investigation and clinical reports have shown that the combination of standard chemotherapy with PI3K inhibitors reduces tumor growth but drug-resistance often occurs. To identify resistance mechanisms to PI3K inhibitors, I will generate in vivo models of drug-resistance (Aim 3). My studies will use both hypothesis driven and unbiased approaches, they should: 1. better elucidate transformation of MSC and the resulting tumor heterogeneity, 2. pinpoint novel targets/biomarkers. Ultimately this knew knowledge should result in better therapies for patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MSCFATE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MSCFATE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More  

ReSOLeS (2019)

New Reconfigurable Spectrum Optical Fibre Laser Sources

Read More